Related references
Note: Only part of the references are listed.Ibrutinib brain distribution: a preclinical study
Lauriane Goldwirt et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Characterization of genomic alterations in primary central nervous system lymphomas
Soheil Zorofchian et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma
Mei Zheng et al.
NEUROPATHOLOGY (2017)
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Christian Grommes et al.
CANCER DISCOVERY (2017)
Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma
Toshikatu Kaburaki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas
T. Nakamura et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2016)
Genomic characterization of primary central nervous system lymphoma
Kazutaka Fukumura et al.
ACTA NEUROPATHOLOGICA (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
Hiroki Akiyama et al.
CANCER SCIENCE (2016)
PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA
Harish Raja et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates
Irina Bonzheim et al.
BLOOD (2015)
Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations
So Yamada et al.
LEUKEMIA & LYMPHOMA (2015)
A novel MYD88 mutation, L265RPP, in Waldenstrom macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival
T. Nagao et al.
BLOOD CANCER JOURNAL (2015)
CD798 and MYD88 mutations in diffuse Large B-cell Lymphoma
Yuil Kim et al.
HUMAN PATHOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Multicolor Flowcytometric Immunophenotyping Is a Valuable Tool for Detection of Intraocular Lymphoma
Tom Missotten et al.
OPHTHALMOLOGY (2013)
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
W. Kraan et al.
BLOOD CANCER JOURNAL (2013)
Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma
Keisuke Kimura et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience
S. Frenkel et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features
SE Coupland et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2004)
Share Paper
